Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.63 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | F7 | P08709 | 1/20 | 0.58 |
| ▸ | F3 | P13726 | 1/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602545 | 0.87 | EIF4A3 (0.58) | PIN1SMAD3KDM4EHSD17B10HPGD | |
| SCHEMBL30180701 | 0.87 | EIF4A3 (0.58) | PIN1SMAD3KDM4EHSD17B10HPGD | |
| SCHEMBL6512084 | 0.86 | PIN1 (0.58) | PIN1SMAD3KDM4EHSD17B10HPGD | |
| SCHEMBL24872303 | 0.85 | KDR (0.48) | PIN1SMAD3KDM4EHSD17B10HPGD | |
| SCHEMBL20764374 | 0.84 | NPC1 (0.54) | PIN1SMAD3KDM4EHSD17B10HPGD | |
| Indole-2-Carboxylic Acid SCHEMBL6517127 | 0.83 | KDM4E (0.56) | PIN1SMAD3KDM4EHSD17B10HPGD | |
| SCHEMBL6513729 | 0.83 | KDM4E (0.58) | PIN1SMAD3KDM4EHSD17B10HPGD | |
| SCHEMBL22718578 | 0.80 | KCNK3 (0.55) | PIN1KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL1474801 | 0.79 | KDM4E (0.70) | KDM4EHSD17B10HPGDALDH1A1LMNA | |
| SCHEMBL6518462 | 0.79 | PIN1 (0.54) | PIN1SMAD3KDM4EHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
| WO-2005066180-A9 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-09-25 | — | — | WO | disclosed |
| WO-2005066180-A9 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-09-25 | — | — | WO | disclosed |
| WO-2005066180-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| US-20050026987-A1 | CBI analogues of the duocarmycins and CC-1065 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2004101767-A2 | CBI ANALOGUES OF THE DUOCARMYCINS AND CC-1065 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-0273418-B1 | Heat-sensitive recording material using chromeno compound | KANZAKI PAPER MFG CO LTD (JP) | 1993-11-24 | — | — | EP | disclosed |
| EP-0249885-B1 | HEAT-SENSITIVE RECORDING MATERIAL | KANZAKI PAPER MANUFACTURING COMPANY LIMITED (JP) | 1992-01-02 | — | — | EP | disclosed |
| EP-0234540-B1 | HEAT-SENSITIVE RECORDING MATERIAL | KANZAKI PAPER MANUFACTURING COMPANY LIMITED (JP) | 1991-10-16 | — | — | EP | disclosed |
| US-4803193-A | COLORFASTNESS; READABLE BY OPTICAL CHARACTER-READING DEVICES | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1989-02-07 | — | — | US | disclosed |
| US-4794101-A | MIXTURE OF PHTHALIDE DYE, FLUORAN COMPOUND AND POLYVALENT METAL SALT OF AN AROMATIC CARBOXYLIC ACID | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1988-12-27 | — | — | US | disclosed |
| EP-0273418-A2 | Heat-sensitive recording material using chromeno compound | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1988-07-06 | — | — | EP | disclosed |
| US-4731353-A | METAL SALT OF INDOLE-2-CARBOXYLIC ACID COLOR DEVELOPER | KANZAKI PAPER MANUFACTURING COMPANY, LIMITED (JP) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026987-A1 | CBI analogues of the duocarmycins and CC-1065 | CCNI, SP1, DCK | PIN1 1289/4885SMAD3 2119/4885KDM4E 1508/4885 |
| US-20080234260-A1 | Cysteine Protease inhibitors | CTSS, CTSZ, CTSK | PIN1 595/4885SMAD3 674/4885KDM4E 2541/4885 |
| US-20110112089-A1 | Cysteine Protease Inhibitors | CTSS, CTSZ, CTSK | PIN1 672/4885SMAD3 769/4885KDM4E 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.